Source:http://linkedlifedata.com/resource/pubmed/id/15172641
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
7
|
| pubmed:dateCreated |
2004-6-2
|
| pubmed:abstractText |
We evaluated the orally administered S-1, in combination with ionizing radiation both in vivo and in vitro against human oral cancer cell lines. Human oral cancer cell lines were used as subcutaneous xenografts in nude mice. S-1 (10 mg/kg) was administered orally 1 h before radiation treatments (1.5 Gy), or 1 h after radiation for five consecutive days. Apoptotic cells were detected by TUNEL method. For in vitro analysis, attached cells were treated with S-1 (50 microg/ml) for 1 h and then irradiated (3, 6, 9, 12, 15 Gy), or they were treated with S-1 for 1 h after radiation. Cell survival was determined by clonogenic assay. The combination of S-1 and radiation was more effective than either agent alone. In addition, S-1 administration before radiation was more effective than S-1 administration after radiation. Moreover, the combination of S-1 and radiation could induce apoptosis significantly than either agent alone (P < 0.01). In vitro clonogenic survival experiments demonstrated the dose enhancement ratio of 1.22 (radiation + S-1), 1.45 (S-1 + radiation) in B88 cells, and 1.16 (radiation + S-1), 1.28 (S-1 + radiation) in HSG cells. These data demonstrate that the combination of S-1 and fractionated radiotherapy is more effective against human oral cancer xenografts than either agent alone, and that S-1 administration before radiation is more effective than after radiation, suggesting a potential clinical applicability of combination treatment of S-1 and radiation in oral cancer therapies.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Drug Combinations,
http://linkedlifedata.com/resource/pubmed/chemical/Oxonic Acid,
http://linkedlifedata.com/resource/pubmed/chemical/Pyridines,
http://linkedlifedata.com/resource/pubmed/chemical/S 1 (combination),
http://linkedlifedata.com/resource/pubmed/chemical/Tegafur
|
| pubmed:status |
MEDLINE
|
| pubmed:month |
Aug
|
| pubmed:issn |
1368-8375
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
40
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
713-9
|
| pubmed:dateRevised |
2004-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:15172641-Animals,
pubmed-meshheading:15172641-Antimetabolites, Antineoplastic,
pubmed-meshheading:15172641-Apoptosis,
pubmed-meshheading:15172641-Carcinoma, Squamous Cell,
pubmed-meshheading:15172641-Cell Survival,
pubmed-meshheading:15172641-Combined Modality Therapy,
pubmed-meshheading:15172641-Drug Combinations,
pubmed-meshheading:15172641-Humans,
pubmed-meshheading:15172641-In Situ Nick-End Labeling,
pubmed-meshheading:15172641-Male,
pubmed-meshheading:15172641-Mice,
pubmed-meshheading:15172641-Mice, Inbred BALB C,
pubmed-meshheading:15172641-Mice, Nude,
pubmed-meshheading:15172641-Mouth Neoplasms,
pubmed-meshheading:15172641-Neoplasm Transplantation,
pubmed-meshheading:15172641-Oxonic Acid,
pubmed-meshheading:15172641-Pyridines,
pubmed-meshheading:15172641-Tegafur,
pubmed-meshheading:15172641-Transplantation, Heterologous,
pubmed-meshheading:15172641-Tumor Cells, Cultured,
pubmed-meshheading:15172641-Tumor Stem Cell Assay
|
| pubmed:year |
2004
|
| pubmed:articleTitle |
Combined effects of the oral fluoropyrimidine anticancer agent, S-1 and radiation on human oral cancer cells.
|
| pubmed:affiliation |
Second Department of Oral and Maxillofacial Surgery, School of Dentistry, University of Tokushima, 3-18-15 Kuramoto-cho, 770-8504, Japan. harako@dent.tokushima-u.ac.jp
|
| pubmed:publicationType |
Journal Article
|